UK-DTOP model shows marked improvement compared with traditional Kidney Donor Risk Index
THURSDAY, Oct. 24, 2024 (HealthDay News) — The U.K. Deceased Donor Kidney Transplant Outcome Prediction (UK-DTOP) model, developed using advanced artificial intelligence, demonstrates superior calibration and discrimination for predicting kidney graft survival, according to a study published online Oct. 22 in Renal Failure.
Hatem Ali, from University Hospitals of Coventry and Warwickshire in the United Kingdom, and colleagues analyzed data from the U.K. Transplant Registry, including 29,713 transplant cases between 2008 and 2022, to assess the predictive performance of the XGBoost, Random Survival Forest, and Optimal Decision Tree machine learning models.
The researchers found that XGBoost demonstrated exceptional performance, with the highest concordance index (0.74) and an area under the curve consistently above 0.73. Compared with the traditional Kidney Donor Risk Index, which achieved a concordance index of 0.57, the UK-DTOP model exhibited marked improvement. Calibration assessments using the Integrated Brier Score further highlighted the advanced capabilities of the XGBoost model, showing a score of 0.14, indicating precise survival probability predictions. Five distinct clusters were identified based on donor and transplant characteristics using unsupervised learning via k-means clustering; significant survival outcome variations were confirmed across the clusters in further analysis using Bayesian Cox regression.
“Our findings suggest that kidney allocation policies should be updated to include more detailed risk stratification,” the authors write. “This could lead to advanced models that better account for donor complexity, improve transplant outcomes, and aid in better decision-making when accepting organ offers.”
Socioeconomic Factors, Comorbidities Tied to Late-Onset Depression in Long-Term Cancer Survivors
Timing of Immune Checkpoint Inhibitor Administration Affects Small Cell Lung Cancer Survival
Appropriate Duration of ADT in Prostate Cancer Depends on Risk
Inaugural Report Describes Trends in Pediatric Cancer in U.S.
Chest Wall Irradiation Does Not Improve Survival in Intermediate-Risk Breast Cancer
Pazopanib Well-Tolerated in Young With Primary Multimetastatic Ewing Sarcoma
Enzalutamide + Leuprolide Boosts Overall Survival for Prostate Cancer With High Recurrence Risk
Postdiagnosis Smoking Cessation Significantly Improves Survival in Cancer Survivors